Abivax SA Sponsored ADR (NASDAQ:ABVX) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) have been assigned an average rating of “Moderate Buy” from the fourteen ratings firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $137.1538.

Several research firms recently commented on ABVX. Citigroup restated a “market outperform” rating on shares of Abivax in a research report on Thursday, January 8th. Citizens Jmp increased their target price on shares of Abivax from $114.00 to $131.00 and gave the stock a “market outperform” rating in a research note on Tuesday, December 16th. BTIG Research restated a “buy” rating and set a $150.00 target price on shares of Abivax in a research report on Wednesday, February 25th. Morgan Stanley lifted their price target on Abivax from $101.00 to $145.00 and gave the company an “overweight” rating in a research note on Friday, January 9th. Finally, Wall Street Zen cut Abivax from a “hold” rating to a “sell” rating in a report on Saturday, December 13th.

Hedge Funds Weigh In On Abivax

A number of large investors have recently added to or reduced their stakes in ABVX. Jefferies Financial Group Inc. acquired a new stake in Abivax in the 3rd quarter valued at approximately $38,827,000. Kennedy Capital Management LLC lifted its stake in Abivax by 7.1% during the second quarter. Kennedy Capital Management LLC now owns 241,188 shares of the company’s stock worth $1,845,000 after purchasing an additional 15,997 shares in the last quarter. Federated Hermes Inc. purchased a new position in shares of Abivax during the third quarter worth $8,448,000. Persistent Asset Partners Ltd acquired a new stake in shares of Abivax in the third quarter valued at $815,000. Finally, Atika Capital Management LLC acquired a new stake in shares of Abivax in the third quarter valued at $5,858,000. 47.91% of the stock is currently owned by institutional investors and hedge funds.

Abivax Price Performance

NASDAQ ABVX opened at $102.47 on Monday. Abivax has a 1 year low of $4.77 and a 1 year high of $148.83. The company has a market capitalization of $8.11 billion, a PE ratio of -19.08 and a beta of 1.01. The company has a fifty day moving average of $118.39 and a 200 day moving average of $111.32.

Abivax (NASDAQ:ABVX) last announced its quarterly earnings results on Monday, March 23rd. The company reported ($1.20) earnings per share for the quarter, beating the consensus estimate of ($2.24) by $1.04. The company had revenue of $0.52 million for the quarter, compared to analysts’ expectations of $1.80 million. Research analysts expect that Abivax will post -2.83 earnings per share for the current year.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.